CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis

• Published in: Genetics and molecular research 2015-04, Vol.14 (2), p.3921-3931
• Main Authors: Kuang, L I, Song, W J, Qing, H M, Yan, S, Song, F L
• Format: Article
• Language: English
• Subjects: Antigens, Neoplasm - blood; Antigens, Neoplasm - metabolism; Antigens, Neoplasm - urine; Biomarkers, Tumor - blood; Biomarkers, Tumor - metabolism; Biomarkers, Tumor - urine; Case-Control Studies; Humans; Keratin-19 - blood; Keratin-19 - metabolism; Keratin-19 - urine; Urinary Bladder Neoplasms - blood; Urinary Bladder Neoplasms - metabolism; Urinary Bladder Neoplasms - urine
• ISSN: 1676-5680; 1676-5680
• DOI: 10.4238/2015.April.27.6

The proteolytic region of cytokeratin-19, referred to as CYFRA21-1, is a soluble molecule present in the serum and other body fluids, and is considered a tumor marker in several neoplastic diseases. To examine whether urinary or serum samples containing CYFRA21-1 can be used as biomarkers for bladder cancer, we conducted a comprehensive meta-analysis of 3 case-control studies. In all studies considered, patients with bladder cancer had a higher CYFRA21-1 level than healthy subjects. Subgroup analysis showed that patients with metastatic bladder cancer had a higher CYFRA21-1 level than those with locally invasive disease. However, no significant difference in CYFRA21-1 was observed between patients with stage I and stage II bladder cancer; there was also no difference in patients with stage II local bladder cancer and those with stage III local bladder cancer. Based on our results, CYFRA21-1 level may be a diagnostic biomarker for diagnosing bladder cancer as well as a possible biomarker for differentiation between local and metastatic bladder cancer. However, it cannot be used as a urinary or serum biomarker for differentiating histological stages of local bladder cancer for histological grades I-III.